Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIME-2: Tanespimycin + Bortezomib in Relapsed-Refractory Multiple Myeloma
NCT00514371Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tanespimycin in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Aug 2007; status: completed.
02
Drugs
tanespimycin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00514371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514371.